Compare AMRK & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMRK | ARCT |
|---|---|---|
| Founded | 1965 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 672.1M | 194.1M |
| IPO Year | N/A | N/A |
| Metric | AMRK | ARCT |
|---|---|---|
| Price | $29.25 | $7.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | $33.00 | ★ $38.67 |
| AVG Volume (30 Days) | 351.3K | ★ 943.4K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | ★ 2.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $11,944,284,000.00 | $97,601,000.00 |
| Revenue This Year | $1.32 | N/A |
| Revenue Next Year | $8.68 | N/A |
| P/E Ratio | $96.11 | ★ N/A |
| Revenue Growth | ★ 20.29 | N/A |
| 52 Week Low | $19.39 | $5.85 |
| 52 Week High | $30.50 | $24.17 |
| Indicator | AMRK | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 66.79 | 37.15 |
| Support Level | $25.48 | $6.07 |
| Resistance Level | $27.31 | $6.90 |
| Average True Range (ATR) | 1.07 | 0.42 |
| MACD | 0.37 | 0.41 |
| Stochastic Oscillator | 95.57 | 80.27 |
A-Mark Precious Metals Inc is a precious metal trading company. It is principally engaged in the wholesale of gold, silver, platinum, copper, and palladium bullion and related products in the form of bars, wafers, coins, and grains. The company's operating segment includes Wholesale Sales & Ancillary Services; Secured Lending; and Direct-to-Consumer. It generates majority of its revenue from the Wholesale Trading and Ancillary Services segment. The Wholesale Trading and Ancillary Services segment comprises business units such as Industrial, Coin and Bar, Trading and Finance, Storage, Logistics, and Mint. Geographically, it derives a majority of its revenue from the United States and the rest from Europe, Asia Pacific, Africa, Australia, Canada, South America, and Asia Pacific.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.